Tofenacin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tofenacin
Tofenacin structure.png
Clinical data
Trade namesElamol, Tofacine, Tofalin
Synonymstofenacin hydrochloride (USAN US)
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard100.035.746 Edit this at Wikidata
Chemical and physical data
FormulaC17H21NO
Molar mass255.355 g/mol
3D model (JSmol)

Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma).[1][2][3] It acts as a serotonin-norepinephrine reuptake inhibitor,[4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.[5][6]

See also[edit]

References[edit]

  1. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041. ISBN 978-3-88763-075-1. Retrieved 19 May 2012.
  2. ^ J. Buckingham (1996). Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074. ISBN 978-0-412-54090-5. Retrieved 19 May 2012.
  3. ^ Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. p. 3268. ISBN 978-0-8155-1526-5. Retrieved 19 May 2012.
  4. ^ Gwynn Pennant Ellis; Geoffrey Buckle West (1 January 1978). Progress in Medicinal Chemistry. Elsevier. p. 284. ISBN 978-0-7204-0655-9. Retrieved 19 May 2012.
  5. ^ Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research. 4 (6): 435–40. PMID 800383.
  6. ^ Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry. 22 (6): 246–9. doi:10.1055/s-2007-1014608. PMID 2616635.